Mediolanum International Funds Ltd Purchases Shares of 124,624 Indivior PLC (NASDAQ:INDV)

Mediolanum International Funds Ltd bought a new stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 124,624 shares of the company's stock, valued at approximately $1,240,000. Mediolanum International Funds Ltd owned about 0.09% of Indivior as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of INDV. Toronto Dominion Bank boosted its position in shares of Indivior by 58.0% during the first quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company's stock valued at $44,872,000 after buying an additional 769,000 shares during the period. Susquehanna International Group Ltd. bought a new position in Indivior in the 2nd quarter valued at $3,224,000. Millennium Management LLC increased its stake in Indivior by 48.1% in the second quarter. Millennium Management LLC now owns 493,313 shares of the company's stock worth $7,952,000 after purchasing an additional 160,282 shares during the period. M&G Plc bought a new stake in shares of Indivior during the first quarter worth $2,518,000. Finally, FourWorld Capital Management LLC bought a new position in shares of Indivior in the first quarter worth about $2,215,000. 60.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on INDV. Craig Hallum dropped their target price on shares of Indivior from $20.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, October 11th. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 target price (up from $15.00) on shares of Indivior in a research report on Friday.

Indivior Stock Down 0.9 %

Shares of NASDAQ INDV traded down $0.08 during midday trading on Monday, reaching $8.92. 850,250 shares of the company's stock traded hands, compared to its average volume of 448,245. The company has a market cap of $1.23 billion, a price-to-earnings ratio of 905.00 and a beta of 0.68. The stock's 50 day simple moving average is $10.13 and its 200-day simple moving average is $13.72. The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50. Indivior PLC has a one year low of $7.33 and a one year high of $23.22.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $307.00 million for the quarter, compared to analysts' expectations of $302.25 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. On average, analysts predict that Indivior PLC will post 1.6 EPS for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.